专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008115497A3 SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMSOME COPY NUMBER 审中-公开
标题翻译：用于清除噪声遗传数据的系统和方法，并确定复杂的编号
公开(公告)号：WO2008115497A3
公开(公告)日：2009-05-28
申请号：PCT/US2008003547
申请日：2008-03-17
申请人： GENE SECURITY NETWORK , RABINOWITZ MATTHEW , SWEETKIND-SINGER JOSH , BANJEVIC MILENA , JOHNSON DAVID SCOTT , KIJACIC DUSAN , PETROV DIMITRI , XU JING , DEMKO ZACHARY P
发明人： RABINOWITZ MATTHEW , SWEETKIND-SINGER JOSH , BANJEVIC MILENA , JOHNSON DAVID SCOTT , KIJACIC DUSAN , PETROV DIMITRI , XU JING , DEMKO ZACHARY P
IPC分类号： G06F19/18 , G06F19/20 , G06F19/22 , G06F19/24
CPC分类号： G06F19/22 , G06F19/18 , G06F19/20 , G06F19/24
摘要： Disclosed herein is a system and method for increasing the fidelity of measured genetic data, for making allele calls, and for determining the state of aneuploidy, in one or a small set of cells, or from fragmentary DNA, where a limited quantity of genetic data is available. Genetic material from the target individual is acquired, amplified and the genetic data is measured using known methods. Poorly or incorrectly measured base pairs, missing alleles and missing regions are reconstructed using expected similarities between the target genome and the genome of genetically related individuals. In accordance with one embodiment of the invention, incomplete genetic data from an embryonic cell are reconstructed at a plurality of loci using the more complete genetic data from a larger sample of diploid cells from one or both parents, with or without haploid genetic data from one or both parents. In another embodiment of the invention, the chromosome copy number can be determined from the measured genetic data of a single or small number of cells, with or without genetic information from one or both parents. In another embodiment of the invention, these determinations are made for the purpose of embryo selection in the context of in-vitro fertilization. In another embodiment of the invention, the genetic data can be reconstructed for the purposes of making phenotypic predictions.
摘要翻译：本文公开了一种系统和方法，用于增加测量的遗传数据的保真度，进行等位基因调用，并确定在一组或一组细胞中或从片段DNA中确定非整倍体的状态，其中有限数量的遗传数据是可用的获取，扩增来自目标个体的遗传物质，并使用已知方法测量遗传数据。使用目标基因组与遗传相关个体的基因组之间的预期相似性来重建差或不正确测量的碱基对，缺失的等位基因和缺失区域。根据本发明的一个实施方案，使用来自一个或两个亲本的二倍体细胞的较大样本的更完整的遗传数据，在多个基因座重建来自胚胎细胞的不完全遗传数据，具有或不具有来自一个的单倍体遗传数据或双亲。在本发明的另一个实施方案中，染色体拷贝数可以从单个或少数细胞的测量的遗传数据确定，具有或不具有来自一个或两个亲本的遗传信息。在本发明的另一个实施方案中，这些确定是为了在体外受精的背景下进行胚胎选择的目的。在本发明的另一个实施方案中，为了进行表型预测的目的，可以重建遗传数据。

2. 发明申请

WO2005112922A9 BENZAMIDE COMPOUNDS 审中-公开
标题翻译：苯甲酸化合物
公开(公告)号：WO2005112922A9
公开(公告)日：2006-03-09
申请号：PCT/US2005014131
申请日：2005-04-22
申请人： SAMARITAN PHARMACEUTICALS , UNIV GEORGETOWN , LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS , XU JING
发明人： LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS , XU JING
IPC分类号： A61K31/416
CPC分类号： A61K31/416
摘要： The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供了预防或治疗哺乳动物（例如人）中的病理状况或症状的治疗方法，其中牵涉到病原体如逆转录病毒对哺乳动物细胞的感染性，并且希望抑制其感染性，包括给予需要这种治疗的哺乳动物，有效量的抑制病原性感染性的氨基酸的哌嗪基酰胺的N-苯甲酰胺衍生物，包括其药学上可接受的盐。本发明还提供了用于预防或治疗哺乳动物（例如人）的神经病理学病症或症状的治疗方法，其包括对需要这种治疗的哺乳动物施用有效量的哌嗪基酰胺的N-苯甲酰胺衍生物其氨基酸，包括其药学上可接受的盐。

3. 发明申请

WO2010042747A3 FGF21 MUTANTS AND USES THEREOF 审中-公开
公开(公告)号：WO2010042747A3
公开(公告)日：2010-06-17
申请号：PCT/US2009060045
申请日：2009-10-08
申请人： AMGEN INC , WALKER KENNETH W , GEGG COLIN V JR , HECHT RANDY I , BELOUSKI EDWARD J , LI YUE-SHENG , MICHAELS MARK L , XU JING , ELLISON MURIELLE M
发明人： WALKER KENNETH W , GEGG COLIN V JR , HECHT RANDY I , BELOUSKI EDWARD J , LI YUE-SHENG , MICHAELS MARK L , XU JING , ELLISON MURIELLE M
IPC分类号： C07K14/50 , A61K38/18
CPC分类号： C07K14/50 , A61K38/00 , A61K47/60
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

4. 发明申请

WO2009053865A2 COLLISION AVOIDANCE FOR UPLINK VOIP TRANSMISSION 审中-公开
标题翻译：上网VOIP传输的避险
公开(公告)号：WO2009053865A2
公开(公告)日：2009-04-30
申请号：PCT/IB2008053675
申请日：2008-09-11
申请人： NOKIA CORP , NOKIA INC , WANG HAIFENG , CHEN BIN , WANG BIN , XU JING , ZHOU TING
发明人： WANG HAIFENG , CHEN BIN , WANG BIN , XU JING , ZHOU TING
IPC分类号： H04L1/18
CPC分类号： H04W72/1257 , H04L1/1812 , H04L1/1887 , H04L1/1893 , H04W72/04
摘要： Disclosed is a method the includes determining if a collision will occur between a transmission from a first user equipment that uses a persistently assigned uplink resource (such as for VoIP packet transmissions) and a retransmission from a second user equipment that uses a synchronous non-adaptive automatic repeat request procedure (e.g., synchronous, non-adaptive HARQ). If it is determined that a collision will occur, the method dynamically allocates the first user equipment to another uplink resource to avoid the collision, while if it is determined that the collision will not occur, the first user equipment is not dynamically allocated another uplink resource so that the first user equipment sends its transmission using the persistently assigned uplink resource. The embodiments of this invention pertain to both the base station (e.g., an evolved Node-B) and the user equipment.
摘要翻译：公开了一种方法，包括：确定在来自使用永久分配的上行链路资源的第一用户设备（诸如用于VoIP分组传输）的传输与来自使用同步非自适应的第二用户设备的重传之间是否发生冲突自动重复请求过程（例如，同步，非自适应HARQ）。如果确定会发生冲突，则该方法将第一用户设备动态分配给另一上行链路资源以避免冲突，而如果确定不会发生冲突，则不向第一用户设备动态分配另一上行链路资源以便第一用户设备使用持久分配的上行链路资源发送其传输。本发明的实施例涉及基站（例如，演进节点B）和用户设备。

5. 发明申请

WO2008073450A2 BENZAMIDE COMPOUNDS 审中-公开
标题翻译：苯酰胺化合物
公开(公告)号：WO2008073450A2
公开(公告)日：2008-06-19
申请号：PCT/US2007025390
申请日：2007-12-12
申请人： UNIV GEORGETOWN , SAMARITAN PHARMACEUTICALS INC , LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS , XU JING
发明人： LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS , XU JING
IPC分类号： A61K31/497
CPC分类号： A61K31/497 , C07D209/20
摘要： The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof, wherein the pathogen is Avian Influenza, Avian Influenza A, Influenza A, Influenza B, hepatitis B virus, or hepatitis C virus. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供了用于预防或治疗哺乳动物例如人的病理状态或症状的治疗方法，其中涉及病原体对哺乳动物细胞的感染性并且需要抑制其感染性，包括对需要这种疗法是有效量的抑制病原性感染性的氨基酸哌嗪酰胺的N-苯甲酰胺衍生物，包括其药学上可接受的盐，其中病原体是禽流感，甲型禽流感，甲型流感，甲型流感，乙型肝炎 B病毒或丙型肝炎病毒。本发明还提供了用于预防或治疗哺乳动物（例如人）的神经病理状况或症状的治疗方法，其包括向需要这种治疗的哺乳动物施用有效量的本发明的哌嗪基酰胺的N-苯甲酰胺衍生物其氨基酸，包括其药学上可接受的盐。

6. 发明申请

WO2013116587A3 MEDIUM VOLTAGE DC COLLECTION SYSTEM 审中-公开
标题翻译：中压直流采集系统
公开(公告)号：WO2013116587A3
公开(公告)日：2014-06-19
申请号：PCT/US2013024255
申请日：2013-02-01
申请人： ABB RESEARCH LTD , PAN JIUPING , KIM HONGRAE , LI JUN , XU JING , SASTRY JYOTI , ARSHAD WAQAS
发明人： PAN JIUPING , KIM HONGRAE , LI JUN , XU JING , SASTRY JYOTI , ARSHAD WAQAS
IPC分类号： H02J3/38
CPC分类号： H02J1/102 , H02J3/36 , H02J3/386 , H02J4/00 , H02M2007/4835 , Y02E10/763 , Y02E60/60 , Y10T307/707
摘要： A power generation system (10) includes at least one generator (16) having at least two sets of stator windings, an active rectifier (12) comprising power cell based modular converters associated with each set of generator windings. Each set of windings is connected to an AC voltage side of the associated active rectifier (32), with each active rectifier (32) having a positive DC voltage output (50A) and a negative DC voltage output (52B). The DC voltage outputs of active rectifiers are connected to each other in series. A medium voltage DC (MVDC) collection network comprises positive pole cables (62) and negative pole cables (64), wherein each positive pole cable (62) is connected to the positive DC voltage output (50B) of a first active rectifier (32) and each negative pole cable (64) is connected to the negative DC voltage output of a last active rectifier (32). A substation (68) receives the negative and positive pole cables of the MVDC collection network for further transformation and transmission.
摘要翻译：发电系统（10）包括具有至少两组定子绕组的至少一个发电机（16），包括与每组发电机绕组相关联的基于功率单元的模块转换器的有源整流器（12）。每组绕组连接到相关联的有源整流器（32）的AC电压侧，每个有源整流器（32）具有正的直流电压输出（50A）和负的直流电压输出（52B）。有源整流器的直流电压输出串联连接。中压直流（MVDC）收集网络包括正极电缆（62）和负极电缆（64），其中每个正极电缆（62）连接到第一有源整流器（32）的正直流电压输出（50B）），并且每个负极电缆（64）连接到最后一个有源整流器（32）的负DC电压输出。变电站（68）接收MVDC收集网络的负极和正极电缆，用于进一步的变换和传输。

7. 发明申请

WO2010129600A3 FGF21 MUTANTS AND USES THEREOF 审中-公开
标题翻译： FGF21突变体及其用途
公开(公告)号：WO2010129600A3
公开(公告)日：2011-04-21
申请号：PCT/US2010033614
申请日：2010-05-04
申请人： AMGEN INC , BELOUSKI EDWARD JOHN , ELLISON MURIELLE MARIE , HAMBURGER AGNES EVA , HECHT RANDY IRA , LI YUE-SHENG , MICHAELS MARK LEO , SUN JEONGHOON , XU JING
发明人： BELOUSKI EDWARD JOHN , ELLISON MURIELLE MARIE , HAMBURGER AGNES EVA , HECHT RANDY IRA , LI YUE-SHENG , MICHAELS MARK LEO , SUN JEONGHOON , XU JING
IPC分类号： A61K38/18 , C07K14/50
CPC分类号： C07K14/50 , A61K38/00 , C07K2319/30
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
摘要翻译：本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。

8. 发明申请

WO2009149171A4 FGF21 MUTANTS AND USES THEREOF 审中-公开
标题翻译： FGF21突变体及其用途
公开(公告)号：WO2009149171A4
公开(公告)日：2010-05-06
申请号：PCT/US2009046113
申请日：2009-06-03
申请人： AMGEN INC , BELOUSKI EDWARD JOHN , ELLISON MURIELLE MARIE , HAMBURGER AGNES EVA , HECHT RANDY IRA , LI YUE-SHENG , MICHAELS MARK LEO , SUN JEONGHOON , XU JING
发明人： BELOUSKI EDWARD JOHN , ELLISON MURIELLE MARIE , HAMBURGER AGNES EVA , HECHT RANDY IRA , LI YUE-SHENG , MICHAELS MARK LEO , SUN JEONGHOON , XU JING
IPC分类号： A61K38/18 , C07K14/50
CPC分类号： C07K14/50 , A61K38/00 , C07K16/18 , C07K2319/30
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
摘要翻译：本发明提供编码FGF21突变多肽的核酸分子，FGF21突变多肽，包含FGF21突变多肽的药物组合物，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。

9. 发明申请

WO2005057824A3 DIRECT-SEQUENCE CDMA METHOD AND DEVICE 审中-公开
标题翻译：直接序列CDMA方法和设备
公开(公告)号：WO2005057824A3
公开(公告)日：2006-04-13
申请号：PCT/IB2004003284
申请日：2004-10-08
申请人： NOKIA CORP , NOKIA INC , WANG HAIFENG , XU JING , CHEN MING , CHENG SHIXIN
发明人： WANG HAIFENG , XU JING , CHEN MING , CHENG SHIXIN
IPC分类号： H04B7/216 , H04L20060101 , H04L5/02 , H04L25/03 , H04L27/26 , H04B7/00
CPC分类号： H04L25/03159 , H04L5/026 , H04L27/2607 , H04L2025/03522 , H04L2025/03617
摘要： In code division multiple access communications wherein a plurality of data streams carrying a plurality of transmit symbols are spread by a plurality of assigned spread code, the data streams are divided into a plurality of data blocks and a plurality of prefixes in symbol-level are added to the data blocks prior to the data streams being spread and combined for transmission. At the receive side, the prefixes are removed from the received data stream in the time domain and the prefix-removed data stream is converted into a transformed signal in the frequency domain. A feed-forward filter is used to implement a joint equalization and despreading operation by element-by-element multiplications in frequency domain. A feedback filter is used to remove the inter-symbol interference and update the feed-forward filter through a feedback loop.
摘要翻译：在码分多址通信中，其中携带多个发送符号的多个数据流被多个分配的扩展码扩展，将数据流分成多个数据块，并且添加符号级中的多个前缀在数据流被传播和组合用于传输之前到数据块。在接收侧，在时域中从接收的数据流中去除前缀，并将前缀去除的数据流转换成频域中的变换信号。前馈滤波器用于通过频域中的逐个元素乘法实现联合均衡和解扩操作。反馈滤波器用于消除符号间干扰，并通过反馈回路更新前馈滤波器。

10. 发明申请

WO2013033452A2 METHOD OF TREATING OR AMELIORATING TYPE 1 DIABETES USING FGF21 审中-公开
标题翻译：使用FGF21治疗或改善1型糖尿病的方法
公开(公告)号：WO2013033452A2
公开(公告)日：2013-03-07
申请号：PCT/US2012053216
申请日：2012-08-30
申请人： STANISLAUS SHANAKA , XU JING , AMGEN INC , ELLISON MURIELLE MARIE
发明人： STANISLAUS SHANAKA , XU JING , ELLISON MURIELLE MARIE
IPC分类号： A61K38/18
CPC分类号： A61K38/1825
摘要： Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease
摘要翻译：提供了使用FGF21多肽治疗代谢疾病和病症的方法。在各种实施方案中，代谢疾病或病症是1型糖尿病，肥胖症，血脂异常，升高的葡萄糖水平，升高的胰岛素水平，糖尿病性肾病，神经病变，视网膜病变，缺血性心脏病，外周血管疾病和脑血管疾病

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式